You may request services if you are an investigator in academia, a not-for-profit organization, industry, or government in the United States or worldwide. You need not be a grantee of NIAID or another National Institutes of Health Institute or Center. Look to each resource for further eligibility information.
Central resource includes development and refinement of animal models, in vivo screening, and efficacy testing. Services are provided to study the full range of pathogens, including bacteria, viruses, parasites, fungi, and other agents such as toxins and prion proteins.
The BEI Resources Repository is a central repository that supplies organisms and reagents to the broad community of microbiology and infectious diseases researchers.
The National Biocontainment Laboratories (NBLs) and Regional Biocontainment Laboratories (RBLs) provide BSL4/3/2 and BSL3/2 biocontainment facilities, respectively, for research on biodefense and emerging infectious disease agents.
The Bioinformatics Resource Centers provide data, tools, and services, which can be accessed through publicly available sites. Each of the BRCs specialize in different groups of pathogens, including viruses such as influenza.
NIAID develops and applies bioinformatics tools for sequencing and alignment, structural analysis and prediction, genome annotation, and simulations and 3D modeling.
The Centers of Excellence for Influenza Research and Surveillance (CEIRS) provides the BEI Resources Repository with high-priority reagents. Non-BEI reagents may be available from CEIRS researchers upon request.
The Functional Genomics program aims to generate experimental data to determine the biochemical function(s) of hypothetical genes, unknown open reading frames, and noncoding RNAs. The program distributes data, software, and reagents generated from the research projects to the broader scientific community.
The Genomic Centers use and develop or improve innovative applications of genomic technologies, such as RNA sequencing and metagenomics, and provide rapid and cost-efficient production of high-quality genome sequences of microorganisms, invertebrate vectors of infectious diseases, and hosts and host microbiomes.
The In Vitro Assessment for Antimicrobial Activity includes screening products for antimicrobial activity and developing and performing or providing in vitro assays for bacteria and fungi, viruses, parasites and vectors, and toxins.
For international research funded by Division of Microbiology and Infectious Diseases, the ICSSC provides consultation and assistance to investigators for protocol development, site assessment, data management, case report form development, biostatistics, training, and workshops.
The Phase I Clinical Trial Units for Therapeutics support the design, development, implementation, and conduct of Phase I clinical trials to assess safety, pharmacokinetics, and/or pharmacodynamics of licensed and investigational therapeutic products, including immunomodulatory agents and monoclonal antibodies, against viral (other than HIV), bacterial, parasitic, and fungal pathogens, including NIAID priority biodefense pathogens and emerging and re-emerging infectious diseases.
The Structural Genomics Centers apply state-of-the-art high-throughput technologies and methodologies to experimentally characterize the 3-D atomic structure of proteins or other molecules having an important biological role in human pathogens and infectious diseases.
The Systems Biology programs develop and validate predictive models of infectious disease initiation, progression, and outcomes. The programs provide data and reagents that result from the research conducted and provide training for the broader infectious disease scientific community to promote the use of the systems biology approach. Several of these programs are relevant for influenza researchers, including FluDyNeMo, FluOmics, and Omics-LHV.
The Therapeutic Development Services program offers a collection of preclinical services to support the development of products intended for use in the cure, mitigation, diagnosis, or treatment of disease caused by a pathogen or certain toxins, including interventional agents and biopharmaceutical products.
The services are intended for use in the investigation, control, prevention, and treatment of infectious diseases other than HIV. They include vaccine testing and vaccine manufacturing.
Vaccine and Treatment Evaluation Units conduct a broad range of studies including Phase I, Phase II, and Phase IV clinical trials, as well as a variety of other studies, including epidemiology studies and studies in international settings.
This resource provides GMP-quality candidate vaccine viruses for zoonotic influenza.